Orbimed Capital LLC, Director at ARS Pharmaceuticals, Inc. (SPRY), sold 83,695 shares at $13.00 ($1.1M) on 2024-08-26, disclosed to the SEC on 2024-08-28.
Open-market sale of $1.1M SPRY by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| ARQT | SELL | 2022-04-08 | $25.4M | — | Filing → |
| RPTX | SELL | 2021-08-30 | $993K | — | Filing → |
| RPTX | SELL | 2021-08-25 | $1.2M | — | Filing → |